Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta TianQing Pharma the rights to its CD3/EpCAM bispecific antibody, M701, in Mainland China. Chi Ta Tian Qing Pharma will pay YZY Biopharma an upfront payment of up to RMB 315 million, plus additional development milestone payments.
M701, a biopharmaceutical Class 1 new drug independently developed by YZY Biopharma, is intended for the treatment of malignant pleural effusion and malignant ascites caused by tumors. It is currently in Phase III clinical trials and is the first domestically developed CD3/EpCAM bispecific antibody to enter clinical trial stages in China. In February 2024, M701 received approval from the National Medical Products Administration (NMPA) to proceed with Phase III registration clinical trials for malignant ascites, which have now enrolled more than half of the required patients. Additionally, M701 is undergoing a Phase II clinical trial for malignant pleural effusion caused by non-small cell lung cancer.- Flcube.com
